October 30, 2014
Company Name:
Representative:
Headquarters:
Contact:
URL:

Japan Tissue Engineering Co., Ltd. (J-TEC)
Yosuke Ozawa, President and CEO(Code: 7774 JQ)
6-209-1 Miyakitadori, Gamagori, Aichi, Japan
Masahito Obayashi
Director, Corporate Management & Administration Dept.
http://www.jpte.co.jp/english/

Notification Regarding the Exercise of Subscription Rights
Through Private Allocation to a Third Party
Japan Tissue Engineering Co., Ltd. (hereinafter referred to as “J-TEC”) notifies that, regarding thebelow-mentioned subscription rights through private allocation to a third party issued by J-TEC as of March 31,2014, Fujifilm Holdings Corporation (hereinafter referred to as “Fujifilm Holdings”) is expected to exercise thesubscription rights within this year through its allotted destination, Fujifilm Corporation (hereinafter referred to as“Fujifilm”), as described in the material released today, “Japan Tissue Engineering Co., Ltd. to become aconsolidated subsidiary.”
In addition, as of September 30, 2014, the total amount of J-TEC shares held by Fujifilm Holdings, including theshares held by Fujifilm (40.97%) and shares held by J-TEC’s major shareholder Toyama Chemical Co., Ltd.
(4.50%) affiliated with Fujifilm Group, amounts to 45.47%. Therefore, the exercise of this transaction ofsubscription rights will make the share ratio of Fujifilm Holdings 50.33%, resulting in prospects that Fujifilm
Holdings will become the parent company of J-TEC.
Details
1. Overview of the issuance of share acquisition rights
6th Subscription Right of Japan Tissue Engineering Co.,
(1)
Name of subscription rightLtd.
(2)
Total number of subscription rights
18,000(3)
Issue price
30,000 yen per unit of subscription rights
1)(4)Total amount of issue price
540,000,000 yen(5)Type and number of objective
18,000 common sharesshares2)(6)
Subscription or allocation method
By means of private allocation to a third party(Allotment, Allotted number)(Fujifilm Corporation - 18,000)(7)
Allocation date
March 31, 2014
(8) The sum of the amount paid for the
Subscription Rights Issuance and the
7,380,000,000 yen
amount to be paid for the exercise of theSubscription Rights(9)
Exercised price2)
380,000 yen per share(10)
Term of exercise
From April 1, 2014 to March 31, 2019
Note 1) The payment for the total amount of issued price of the subscription rights in this transaction (540million yen) has been completed as of March 31, 2014. The amount received by J-TEC upon theexercise of the 18,000 subscription rights in this transaction will be 6,840 million yen.
1/2

Note 2) J-TEC has performed a stock split of 200-for-1 as of April 1, 2014. As a result, the “type and numberof objective shares” and “exercised price” will be adjusted to “3,600,000 common shares” and “1,900yen per share,” respectively.
2. Future prospects
With the exercise of subscription rights in this transaction, J-TEC will strive to strengthen its financial baseand, at the same time, enhance and accelerate the following domains:
 Cooperation with Fujifilm Group in existing business areas Product development leveraging the Pharmaceutical and Medical Device Act (Revised JapanesePharmaceutical Affairs Act) Business development leveraging the Act on the Safety of Regenerative Medicine
 Development of regenerative medicine products utilizing recombinant peptide (RCP) with superior
biocompatibility developed by Fujifilm
 Overseas business development

2/2